Compare · CERS vs INFY
CERS vs INFY
Side-by-side comparison of Cerus Corporation (CERS) and Infosys Limited (INFY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CERS and INFY operate in EDP Services (Technology), so they compete in similar markets.
- INFY is the larger of the two at $53.42B, about 134.7x CERS ($396.7M).
- Over the past year, CERS is up 47.8% and INFY is down 25.8% - CERS leads by 73.5 points.
- INFY has been more active in the news (8 items in the past 4 weeks vs 4 for CERS).
- INFY has more recent analyst coverage (25 ratings vs 3 for CERS).
- Company
- Cerus Corporation
- Infosys Limited
- Price
- $1.98+4.49%
- $12.87-0.58%
- Market cap
- $396.7M
- $53.42B
- 1M return
- +7.03%
- -2.20%
- 1Y return
- +47.76%
- -25.78%
- Industry
- EDP Services
- EDP Services
- Exchange
- NASDAQ
- NYSE
- IPO
- 1997
- News (4w)
- 4
- 8
- Recent ratings
- 3
- 25
Cerus Corporation
Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation has collaboration with LifeSouth Community Blood Centers to manufacture INTERCEPT Fibrinogen Complex. The company was incorporated in 1991 and is headquartered in Concord, California.
Infosys Limited
Infosys Limited, together with its subsidiaries, provides consulting, technology, outsourcing, and next-generation digital services in North America, Europe, India, and internationally. It provides application development and management, independent validation, product engineering and management, infrastructure management, enterprise application management, and support and integration services. The company's products and platforms include Finacle, a core banking solution; Edge suite of products; Infosys Nia, an artificial intelligence platform; Infosys McCamish - an insurance platform; Wingspan, a customizable learning platform; Stater mortgage servicing platform; Panaya automation suite; and Skava, an e-commerce suite. The company serves clients in the financial services and insurance, life sciences and healthcare, manufacturing, retail, consumer packaged goods and logistics, hi-tech, communications, telecom OEM, media, energy, utilities, resources, services, and other industries. It has collaboration agreements with Rolls-Royce, BP plc, Newmont Corporation, RXR Realty, Majesco Limited, and Centre for Accessibility Australia. The company was formerly known as Infosys Technologies Limited and changed its name to Infosys Limited in June 2011. Infosys Limited was incorporated in 1981 and is headquartered in Bengaluru, India.
Latest CERS
- SEC Form DEFA14A filed by Cerus Corporation
- SEC Form DEF 14A filed by Cerus Corporation
- Cerus Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Cerus Corporation to Release First Quarter 2026 Financial Results on April 30, 2026
- SEC Form 4 filed by Green Kevin Dennis
- SEC Form 4 filed by Jensen Chrystal
- Amendment: SEC Form SCHEDULE 13G/A filed by Cerus Corporation
- Chief Legal Officer Jensen Chrystal sold $187,277 worth of shares (113,008 units at $1.66), decreasing direct ownership by 11% to 946,131 units (SEC Form 4)
- Chief Operating Officer Jayaraman Vivek K sold $273,769 worth of shares (165,200 units at $1.66), decreasing direct ownership by 9% to 1,747,674 units (SEC Form 4)
- President and CEO Greenman William Mariner sold $742,023 worth of shares (447,757 units at $1.66), decreasing direct ownership by 8% to 4,998,493 units (SEC Form 4)
Latest INFY
- SEC Form 6-K filed by Infosys Limited
- SEC Form 6-K filed by Infosys Limited
- Revenue crosses $20 billion mark with resilient growth of 3.1% in FY 26 in constant currency
- Infosys Announces Strategic Collaboration with OpenAI to Accelerate Enterprise AI Transformation and Unlock AI Value at Scale
- SEC Form 6-K filed by Infosys Limited
- 7-Time Grand Slam Champion Carlos Alcaraz is Infosys Global Brand Ambassador
- Infosys and Harness Announce Strategic Collaboration to Unlock AI Value for Enterprise Transformation and Modernization Programs
- SEC Form 3 filed by new insider Damodaran Nair Sundaram
- SEC Form 3 filed by new insider Parekh Salil S.
- SEC Form 3 filed by new insider Gibbs Michael Nelson